- Home
- THAR vs CISS Comparison
THAR vs CISS Comparison
Compare THAR & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- CISS
- Stock Information
- Founded
- THAR 2017
- CISS 2022
- Country
- THAR United States
- CISS Greece
- Employees
- THAR N/A
- CISS N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- CISS Marine Transportation
- Sector
- THAR Health Care
- CISS Consumer Discretionary
- Exchange
- THAR Nasdaq
- CISS Nasdaq
- Market Cap
- THAR 2.4M
- CISS 2.4M
- IPO Year
- THAR 2022
- CISS N/A
- Fundamental
- Price
- THAR $1.20
- CISS $3.90
- Analyst Decision
- THAR Strong Buy
- CISS
- Analyst Count
- THAR 1
- CISS 0
- Target Price
- THAR $17.00
- CISS N/A
- AVG Volume (30 Days)
- THAR 97.3K
- CISS 62.5K
- Earning Date
- THAR 05-08-2025
- CISS 05-27-2025
- Dividend Yield
- THAR N/A
- CISS N/A
- EPS Growth
- THAR N/A
- CISS N/A
- EPS
- THAR N/A
- CISS N/A
- Revenue
- THAR N/A
- CISS $42,296,101.00
- Revenue This Year
- THAR N/A
- CISS N/A
- Revenue Next Year
- THAR N/A
- CISS N/A
- P/E Ratio
- THAR N/A
- CISS N/A
- Revenue Growth
- THAR N/A
- CISS 47.17
- 52 Week Low
- THAR $0.95
- CISS $2.85
- 52 Week High
- THAR $6.45
- CISS $29.40
- Technical
- Relative Strength Index (RSI)
- THAR 43.85
- CISS 50.21
- Support Level
- THAR $1.05
- CISS $3.20
- Resistance Level
- THAR $1.28
- CISS $3.58
- Average True Range (ATR)
- THAR 0.11
- CISS 0.37
- MACD
- THAR 0.02
- CISS 0.10
- Stochastic Oscillator
- THAR 75.58
- CISS 70.50
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.